Synedgen showcased in the Top 10 Cystic Fibrosis Stories of 2018 by CF News Today

Studies led by Synedgen and Keck Graduate Institute show Ion-Sugar Interaction in Airway Mucus Has Implications for CF.This researchaddresses ion interactions in different kinds of cell surfaces and water-containing gels. Understanding how each type of ion affects the structure, electrical potential, and fluid behavior of the airway-surface layers in the lung has direct implications for designing drug targets that influence pulmonary behavior. Read on Cystic Fibrosis News Today

Life Science Leader features Synspira in its Companies to Watch

SNSP113 is a glycopolymer licensed to Synspira from Synedgen as one of the first therapeutic molecules that uses this research to target airway health. SNSP113 is set to soon enter a Phase 1b clinical trial for treating cystic fibrosis (CF). SNSP113 targets biofilms and restores normal mucus in the lungs of patients with cystic fibrosis. Other compounds in the pipeline target non-CF bronchiectasis, pulmonary infection, and chronic obstructive pulmonary disease (COPD) Read on Life Science Leader